Cardiac troponins (cTn)3 I and T are pervasively used to rule in or rule out acute myocardial infarction and/or assess for myocardial injury, with an abnormal result defined as a troponin concentration greater than the assay-specific 99th percentile (1, 2). High-sensitivity cTn assays (hs-cTnI, hs-cTnT) are being implemented globally and offer refined precision at low concentrations, which allow for enhanced clinical and analytical sensitivity and use of rapid rule-out strategies and algorithms. However, although hs-cTn assays continue to improve from an analytical perspective, the clinical performance gap continues to widen between automated/central laboratory hs-cTn assays vs point-of-care (POC) cTn assays. POC cTn testing has demonstrated lower clinical sensitivity with a positive predictive value around 50% (3), thereby resulting in a greater number of patients being undiagnosed, inadequately treated, or discharged in the acute care setting (4, 5). Nonetheless, POC cTn testing may be …

Log in using your username and password

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.